A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.
Jason D LickliterHui K GanMark VoskoboynikSurein ArulanandaBo GaoAdnan NagrialPeter GrimisonMichelle HarrisonJianjun ZouLianshan ZhangStacey LuoMichael LahnHoward KallenderAndrea MannucciCatello SommaKatherine WoodsAndreas BehrenPablo Fernandez-PenasMichael MillwardTarek MeniawyPublished in: Drug design, development and therapy (2020)
ClinicalTrials.gov Identifier: NCT02492789.